[Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (1)].
The amounts of antigens in the serum of patients with various types of cancer and benign diseases were measured in order to clinically evaluate the NCC-ST-439 EIA kit. From the results of measurements in 583 healthy persons, cut-off values of 4.5 U/ml for males and females 50 years or older and 7.0 U/ml for females 49 or younger were set. The false-positive rate for healthy persons at this time was 5.0%. The positive rates for malignant tumors at these cut-off values were 58.9% for pancreatic carcinoma, 53.1% for cholangiocarcinoma, 41.9% for mammary carcinoma, 36.6% for rectal and colonic carcinoma, 33.3% for hepatocellular carcinoma and 35.3% for carcinoma as a whole. The false-positive rates for benign diseases were 14.0% for pancreatic disease, 9.7% for liver disease, 8.0% for biliary duct disease and 8.3% for benign diseases as a whole. These rates were low when compared with those for other tumor markers. These results showed that NCC-ST-439 is a tumor marker with a high degree of specificity.
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D001661:Biliary Tract Neoplasms / Q000175:diagnosis; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis*; D010190:Pancreatic Neoplasms / Q000175:diagnosis; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D013274:Stomach Neoplasms / Q000276:immunology; D000509:alpha-Fetoproteins / Q000032:analysis
D000911:Antibodies, Monoclonal; D006023:Glycoproteins; D011933:Reagent Kits, Diagnostic; D000509:alpha-Fetoproteins